- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00454571
Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. Determine if pazopanib hydrochloride is able to increase time to progression, as measured by prostate-specific antigen (PSA), after 6 months of limited gonadotropin-releasing hormone (GnRH) agonist therapy comprising leuprolide acetate or goserelin in patients with androgen-sensitive relapsed stage D0 prostate cancer.
SECONDARY OBJECTIVES:
I. Determine the adverse events in patients treated with this regimen. II. To monitor for changes in testosterone in relationship to pazopanib therapy versus observation.
OUTLINE:
Patients receive androgen blockade comprising GnRH agonist therapy (e.g., leuprolide acetate or goserelin acetate) for 6 months. Patients who develop metastases or have PSA progression while on GnRH agonist therapy are removed from the study and placed on total androgen blockade. The remaining patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
ARM II: Patients undergo observation.
After completion of study treatment, patients are followed up periodically for up to 12 months.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637-1470
- University of Chicago Comprehensive Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Hospital and Clinics
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Histologically or cytologically confirmed prostate cancer
- Stage D0
- Must have undergone some definitive local therapy for prostate cancer
- Must be free of macrometastatic disease, as evidenced by computed tomography (CT) scan and bone scan, if serum PSA ≥ 10 ng/mL prior to GnRH agonist therapy
Progressive disease meeting the following criteria: NOTE: Patients who have undergone a prostatectomy and have two detectable, rising serum PSA levels are eligible
- Two consecutive rises in PSA above nadir recorded after definite local therapy
- Serum PSA concentrations must have absolute value of > 0.5 ng/mL (separated by ≥ 2 weeks) prior to beginning GnRH agonist therapy
- PSA < 0.5 ng/mL
- Testosterone < 30 ng/mL
- No measurable disease
- No brain metastases requiring steroid or anticonvulsant therapy
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60- 100%
- Prothrombin time (PT)/international normalization ratio (INR)/partial thromboplastin time (PTT) ≤ 1.2 times upper limit of normal (ULN)
- Bilirubin normal
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN
- Creatinine ≤ 1.5 times ULN OR creatinine clearance > 50 mL/min
- Proteinuria ≤ 1+ on 2 consecutive dipsticks > 1 week apart
- Urine protein: creatinine ratio < 1 OR urine protein < 1.0 g/24 hours
- Fertile patients must use effective double-barrier contraception during study therapy OR completely abstain from sexual intercourse 14 days prior to, during, and for ≥ 21 days after completion of study therapy
- No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or to other agents used in the study
No concurrent uncontrolled illness including, but not limited to, any of the following:
- Ongoing or active infection
- Psychiatric illness or social situations that would preclude compliance with study requirements
- No human immunodeficiency virus (HIV) positivity
No condition that impairs the ability to swallow and retain pazopanib hydrochloride tablets, including any of the following:
- Gastrointestinal tract disease resulting in an inability to take oral medication
- Requirement for intravenous (IV) alimentation
- Prior surgical procedures affecting absorption
- Active peptic ulcer disease
No other conditions, including any of the following:
- Serious or nonhealing wound, ulcer, or bone fracture
- Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- Cerebrovascular accident within the past 6 months
- Myocardial infarction, admission for unstable angina, cardiac angioplasty, or stenting within the past 6 months
- Venous thrombosis within the past 12 weeks
New York Heart Association (NYHA) class III or IV heart failure
- History of currently treated asymptomatic NYHA class II heart failure allowed
Systolic blood pressure (BP) ≤ 140 mm Hg and diastolic BP ≤ 90 mm Hg
- Prior initiation or adjustment of BP medication allowed provided that the average of 3 BP readings at a visit prior to enrollment is < 140/90 mm Hg
- More than 3 months since prior antiandrogen
- More than 4 months since prior orchiectomy or implantable luteinizing LHRH agonist
No prior GnRH agonists except for neoadjuvant or adjuvant therapy associated with local therapy
Patients who have started a GnRH agonist for micrometastatic disease after local therapy allowed provided the following criteria are met:
- Progressive disease
- Willing to discontinue therapy before 6 months have elapsed
- Have signed consent prior to completing 6 months of the initial hormone therapy
- Are within 4 months of initiating GnRH agonist therapy
- No prior or concurrent GnRH antagonist therapy
- No concurrent ketoconazole
No concurrent cytochrome P450 2C9 (CYP2C9) substrates, including any of the following:
Anticoagulants (e.g., warfarin [therapeutic doses only])
- Low molecular weight heparin or prophylactic low-dose warfarin allowed
- Oral hypoglycemics (e.g., glipizide, glyburide, tolbutamide, glimepiride, or nateglinide)
- Ergot derivatives (e.g., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)
- Neuroleptics (e.g., pimozide)
- Erectile dysfunction agents (e.g., sildenafil, tadalafil, or vardenafil)
- Antiarrhythmics (e.g., bepridil, flecainide, lidocaine, mexiletin, amiodarone, quinidine, or propafenone)
- Immune modulators (e.g., cyclosporine, tacrolimus, or sirolimus)
- Miscellaneous medications (e.g., theophylline, quetiapine, risperidone, tacrine, clozapine, or atomoxetine)
No concurrent medications associated with the risk of QTc prolongation and/or Torsades de Pointes
- Replacement of drugs that do not carry these risks allowed
- No other concurrent non-Food and Drug Administration (FDA)-approved agents
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Pazopanib
Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate.
Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
|
Dado PO
Outros nomes:
Outros nomes:
Outros nomes:
|
Comparador Ativo: Observation
Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
|
Outros nomes:
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Median Time to PSA Progression
Prazo: Baseline, every 4 weeks during treatment, and up to 12 months after completion of study treatment
|
The median time to disease progression for the therapy and observation groups will be estimated using the Kaplan-Meier estimate and compared using the log-rank test.
|
Baseline, every 4 weeks during treatment, and up to 12 months after completion of study treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Median PSA Progression-free Survival
Prazo: Time from randomization to PSA progression or death from any cause
|
Kaplan-Meier estimates for PSA progression-free survival will be computed for the pazopanib and active surveillance groups and compared using the log rank test.
The outcome measure is median PSA progression-free survival time.
|
Time from randomization to PSA progression or death from any cause
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Edwin Posadas, University of Chicago Comprehensive Cancer Center
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias Genitais Masculinas
- Doenças prostáticas
- Neoplasias prostáticas
- Efeitos Fisiológicos das Drogas
- Agentes Antineoplásicos
- Agentes Antineoplásicos Hormonais
- Agentes de Controle Reprodutivo
- Agentes de Fertilidade, Feminino
- Agentes de Fertilidade
- Leuprolida
- Goserelina
Outros números de identificação do estudo
- NCI-2009-00202
- N01CM62201 (Concessão/Contrato do NIH dos EUA)
- CDR0000538086 (Identificador de registro: PDQ (Physician Data Query))
- 14954A
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de Próstata Recorrente
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
Ensaios clínicos em cloridrato de pazopanibe
-
Centre Leon BerardGlaxoSmithKlineConcluídoCarcinoma de TireóideFrança
-
Imperial College LondonGlaxoSmithKlineConcluídoNeoplasia ovarianaReino Unido
-
Novartis PharmaceuticalsRescindidoCarcinoma de Células RenaisAustrália, Republica da Coréia
-
Centre Leon BerardRecrutamento
-
PfizerConcluídoCarcinoma metastático de células renais (mRCC)Espanha, Itália, Bélgica, França, Reino Unido, Áustria, Grécia, Holanda
-
Memorial Sloan Kettering Cancer CenterWashington University School of Medicine; University of California, Los Angeles e outros colaboradoresRescindidoSarcoma | Leiomiossarcoma | Tumor Maligno da Bainha do Nervo Periférico | Fibroso Maligno | Histiocitoma/Sarcoma Pleomórfico IndiferenciadoEstados Unidos
-
Heidelberg UniversityDesconhecidoCarcinoma de Células RenaisAlemanha
-
NewLink Genetics CorporationConcluídoCarcinoma de Células Renais MetastáticoRepublica da Coréia, Estados Unidos
-
Institut BergoniéConcluídoTumores Desmóides ProgressivosFrança